Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Wellnex Life Ltd ( (AU:WNX) ) just unveiled an announcement.
Wellnex Life Limited reported a significant increase in sales for the first half of FY25, with total sales reaching $11.94 million, marking a 112% rise from the previous year. This growth is driven by strong brand sales, which soared by 182%, and a notable increase in IP licensing revenue. The company experienced remarkable sales momentum in December 2024, with a 1018% increase compared to the same month in 2023, highlighting its continued expansion and success in brand distribution and awareness. These results underscore Wellnex Life’s strengthened position in the healthcare market and promise further progress in FY25, benefiting stakeholders through expanded brand presence and increased licensing business.
More about Wellnex Life Ltd
Wellnex Life Limited is a consumer healthcare business focused on developing, licensing, and marketing registered products and brands within the healthcare market segment. Since its listing in 2021, it has launched various brands and products available in major retailers, pharmacies, and supermarkets. The company has significant licensing agreements with pharmaceutical companies in Australia and globally, expanding its distribution and global footprint. Recently, Wellnex Life acquired the Australian topical pain relief brand Pain Away, boosting its growth potential and reinforcing its market position both in Australia and overseas.
YTD Price Performance: -3.00%
Average Trading Volume: 7,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €12.14M
Learn more about WNX stock on TipRanks’ Stock Analysis page.
